Pharm 101: Erythropoietin

Class

Haematopoietic growth factor


Pharmacodynamics
  • Glycoprotein produced primarily by kidney
  • Production:
    • Interstitial cells in peritubular capillary bed of kidney (85%)
    • Perivenous hepatocytes in liver (15%)
    • Also brain, uterus, oviducts
  • Causes:
    • Proliferation and differentiation of RBC precursors
    • Release of reticulocytes from bone marrow
  • Takes 2-3 days for effects to take place

Pharmacokinetics
  • Half-life 4-13 hours after IV administration in chronic renal failure

Clinical uses
  • Anaemia secondary to chronic kidney disease
  • Reduce need for RBC transfusion in patients with marrow failure states:
    • Aplastic anaemia
    • Myeloproliferative disroders
    • AIDS

Adverse effects
  • Toxicity is mainly related to rapid Hb rise:
    • Hypertension
    • Thrombosis
  • Allergic reactions are infrequent and mild

References

Pharm 101 700

Pharmacology 101

Top 200 drugs

MBBS (UWA) CCPU Emergency Medicine Trainee with interests in medical education, ECG interpretation, and the use of point-of-care ultrasound in the undifferentiated patient. Co-author of the LITFL ECG Library | Twitter

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.